You are here: Industry Insights > Everest Medicines

News List

Everest Medicines Will Participate in a Clinical Trial with Gilead and MSD to Evaluate Trodelvy? in Combination with KEYTRUDA? (pembrolizumab) in First-Line Metastatic Non-Small Cell Lung Cancer prnasia
January 11, 2022
Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), today announced it will participate in a study pursuant to a clinical trial collaboration between Gilead and MSD...
Everest Medicines Announces Taiwan, China,China FDA Has Accepted New Drug Application for Sacituzumab Govitecan in Second-Line Metastatic Triple-Negative Breast Cancer prnasia
January 04, 2022
Everest Medicines Limited (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products in Asia...
Providence Therapeutics and Everest Medicines announces that PTX-COVID19-B, a mRNA Vaccine for COVID-19, has received approval for inclusion in WHO Solidarity Trial Vaccines (STV) Program prnewswire
December 21, 2021
Providence Therapeutics and Everest Medicines announced today that their COVID-19 vaccine, PTX-COVID19-B, has been recommended by an independent advisory group to be part of the Solidarity Trial Vaccines ("STV") clinical trial.
Everest Medicines Announces the Acceptance of a New Drug Application for Sacituzumab Govitecan in Second-Line Metastatic Triple-Negative Breast Cancer in South Korea prnasia
December 15, 2021
Everest Medicines Limited (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products...
Everest Medicines and Providence Therapeutics Jointly Announce Vaccine Development Strategy to Address Omicron (B.1.1.529) SARS-CoV-2 Variant prnasia
December 01, 2021
Everest Medicines and Providence Therapeutics ("Providence") jointly announced today that the companies have started working on a new version of COVID-19 vaccine specifically targeting the new Omicron variant.
Everest Medicines Initiates Submission of New Drug Application in Hong Kong, S.A.R., China for XeravaTM for the Treatment of Complicated Intra-abdominal Infections prnasia
October 13, 2021
Everest Medicines Limited (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products...
Everest Medicines Announces Approval of Investigational New Drug Application by China NMPA for SPR206 prnasia
September 28, 2021
Everest Medicines (HKEX 1952.HK), a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products that address critical unmet medical needs for patients in Asia...
AbCellera and Everest Medicines Announce Multi-Target Collaboration to Advance New Antibody Therapies prnasia
September 28, 2021
AbCellera (Nasdaq: ABCL) and Everest Medicines Limited (HKEX 1952.HK, "Everest") announced today that they have entered into a multi-year collaboration and license agreement...
Everest Medicines Announces Strategic Commercial Partnership with Global Technology Company, Tencent prnasia
July 12, 2021
Everest Medicines announced that it has entered into a strategic commercial partnership with Tencent, one of the world's largest technology companies, to explore novel ways to optimize meaningful digital engagement with patients and healthcare providers.
Everest Medicines Announces China NMPA Has Granted Priority Review for Sacituzumab Govitecan-hziy in Metastatic Triple-Negative Breast Cancer prnasia
May 21, 2021
Everest Medicines announced that sacituzumab govitecan-hziy (SG) was granted Priority Review by the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA).